Juvenile Macular Degeneration Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2015” report to its store. The report provides an overview of the juvenile macular degeneration’s therapeutic pipeline.

Juvenile Macular Degeneration Therapeutics Pipeline

Juvenile Macular Degeneration Therapeutics Pipeline

The report “Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Oral Mucositis. Stargardt macular degeneration is a genetic eye disorder that causes progressive vision loss. Stargardt disease is the most ordinary form of juvenile macular degeneration. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The anticipated prevalence of Stargardt macular degeneration is 1 in 8,000 to 10,000 persons. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/juvenile-macular-degeneration-stargardt-disease-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and special features on late-stage and discontinued projects. Companies discussed in this Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2015 report include Acucela Inc., Alkeus Pharmaceuticals, Inc., Ocata Therapeutics, Inc., Sanofi.

Drugs profile discussed in this report includes ALK-001, echothiophate iodide, emixustat hydrochloride, Gene Therapy for Stargardt Disease, MA09-hRPE, Small Molecule for Stargardt Disease, StarGen, VSM-20R. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269603 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this “Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2015” report include: Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration; Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt's Macular Degeneration Phase 1 Trial in the United Kingdom; Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials; May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells; Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration 53
Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt's Macular Dystrophy; Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy; Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells; Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone; Dec 17, 2012: ACT Completes HigherDosage Cohort In European Clinical Trial For Stargardt's Macular Dystrophy Using Retinal Pigment Epithelial Cells.

Table of content

List of Tables

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2015
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Acucela Inc., H1 2015
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals, Inc., H1 2015
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Ocata Therapeutics, Inc., H1 2015
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Sanofi, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics - Recent Pipeline Updates, H1 2015

List of Figures

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2015
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets H1 2015
Number of Products by Top 10 Mechanism of Actions H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions H1 2015
Number of Products by Top 10 Routes of Administration H1 2015

Explore more reports on Cancer Drugs Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website